Disk Correlates for Revised Clinical and Laboratory Standards Institute Piperacillin-Tazobactam MIC Breakpoints.
作者信息
Humphries Romney, Tamma Pranita D, Mathers Amy J
机构信息
Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Department of Pediatrics, Johns Hopkins Medical Center, Baltimore, Maryland, USA.
出版信息
J Clin Microbiol. 2022 May 18;60(5):e0024322. doi: 10.1128/jcm.00243-22. Epub 2022 Apr 21.
Abstract
摘要
相似文献
1
Disk Correlates for Revised Clinical and Laboratory Standards Institute Piperacillin-Tazobactam MIC Breakpoints.
J Clin Microbiol. 2022 May 18;60(5):e0024322. doi: 10.1128/jcm.00243-22. Epub 2022 Apr 21.
2
Multicenter Evaluation of the New Etest Gradient Diffusion Method for Piperacillin-Tazobactam Susceptibility Testing of , , and Complex.
J Clin Microbiol. 2020 Jan 28;58(2). doi: 10.1128/JCM.01042-19.
3
Strategies for Updating Piperacillin-Tazobactam Breakpoints.
J Clin Microbiol. 2023 Apr 20;61(4):e0004223. doi: 10.1128/jcm.00042-23. Epub 2023 Mar 15.
4
Deconstructing the 2023 Clinical and Laboratory Standards Institute Revised Piperacillin-Tazobactam Breakpoints Against Pseudomonas aeruginosa.
Clin Infect Dis. 2023 May 24;76(10):1868-1870. doi: 10.1093/cid/ciad012.
5
The Editors' reply to "Letter responding to performance of updated piperacillin-tazobactam breakpoints on the MicroScan antimicrobial susceptibility testing system".
J Clin Microbiol. 2023 Nov 21;61(11):e0069223. doi: 10.1128/jcm.00692-23. Epub 2023 Oct 12.
6
Comparison of Antimicrobial Susceptibility Test Results of Disk Diffusion, Gradient Strip, and Automated Dilution with Broth Microdilution for Piperacillin-Tazobactam.
Microb Drug Resist. 2021 Oct;27(10):1305-1311. doi: 10.1089/mdr.2020.0011. Epub 2021 Sep 28.
7
Possible impact of revisions in disc diffusion breakpoints for aminoglycosides and piperacillin/tazobactam in the 33rd edition of CLSI M100 document on clinical reporting and use in Indian settings with low susceptibility.
Indian J Med Microbiol. 2024 May-Jun;49:100602. doi: 10.1016/j.ijmmb.2024.100602. Epub 2024 May 7.
8
Evaluation of Piperacillin-Tazobactam Testing against by the Phoenix, MicroScan, and Vitek2 Tests Using Updated Clinical and Laboratory Standards Institute Breakpoints.
J Clin Microbiol. 2023 Feb 22;61(2):e0161722. doi: 10.1128/jcm.01617-22. Epub 2023 Jan 31.
9
Breaking Down the Breakpoints: Rationale for the 2022 Clinical and Laboratory Standards Institute Revised Piperacillin-Tazobactam Breakpoints Against Enterobacterales.
Clin Infect Dis. 2023 Nov 30;77(11):1585-1590. doi: 10.1093/cid/ciac688.
10
Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria.
Int J Antimicrob Agents. 2021 May;57(5):106318. doi: 10.1016/j.ijantimicag.2021.106318. Epub 2021 Mar 11.
引用本文的文献
1
Overview of changes in the Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing: M100 32nd and 33rd editions.
J Clin Microbiol. 2025 Sep 10;63(9):e0162323. doi: 10.1128/jcm.01623-23. Epub 2025 Aug 7.
2
Performance of direct-from-blood-culture disk diffusion antibiotic susceptibility testing and its impact on antibiotic adjustment in bloodstream infections at a Malaysian tertiary center.
Microbiol Spectr. 2025 Jun 18:e0286324. doi: 10.1128/spectrum.02863-24.
3
Evaluation of piperacillin-tazobactam disks using contemporary Enterobacterales isolates suggests the need for disk potency optimization.
J Clin Microbiol. 2025 Feb 19;63(2):e0159924. doi: 10.1128/jcm.01599-24. Epub 2025 Jan 10.
4
Evaluation of Piperacillin-Tazobactam Testing against by the Phoenix, MicroScan, and Vitek2 Tests Using Updated Clinical and Laboratory Standards Institute Breakpoints.
J Clin Microbiol. 2023 Feb 22;61(2):e0161722. doi: 10.1128/jcm.01617-22. Epub 2023 Jan 31.
本文引用的文献
1
Variability of Beta-Lactam Broth Microdilution for Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0064021. doi: 10.1128/AAC.00640-21. Epub 2021 Jul 26.
2
Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO Study.
Clin Infect Dis. 2021 Dec 6;73(11):e3842-e3850. doi: 10.1093/cid/ciaa1479.
3
Building a Better Test for Piperacillin-Tazobactam Susceptibility Testing: Would that It Were So Simple (It's Complicated).
J Clin Microbiol. 2020 Jan 28;58(2). doi: 10.1128/JCM.01649-19.
4
Multicenter Evaluation of the New Etest Gradient Diffusion Method for Piperacillin-Tazobactam Susceptibility Testing of , , and Complex.
J Clin Microbiol. 2020 Jan 28;58(2). doi: 10.1128/JCM.01042-19.
5
OXA-1 β-lactamase and non-susceptibility to penicillin/β-lactamase inhibitor combinations among ESBL-producing Escherichia coli.
J Antimicrob Chemother. 2019 Feb 1;74(2):326-333. doi: 10.1093/jac/dky453.
6
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
JAMA. 2018 Sep 11;320(10):984-994. doi: 10.1001/jama.2018.12163.
Zotero 插件